Compare PHAR & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | PAHC |
|---|---|---|
| Founded | 1988 | 1946 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.6B |
| IPO Year | 2020 | 2014 |
| Metric | PHAR | PAHC |
|---|---|---|
| Price | $12.94 | $34.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $38.33 | ★ $41.25 |
| AVG Volume (30 Days) | 10.1K | ★ 362.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | N/A | ★ $833,350,000.00 |
| Revenue This Year | $10.04 | $17.03 |
| Revenue Next Year | $2.51 | $3.82 |
| P/E Ratio | $3,041.22 | ★ $18.98 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $9.54 | $22.71 |
| 52 Week High | $21.34 | $60.08 |
| Indicator | PHAR | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 25.86 |
| Support Level | $11.83 | $25.58 |
| Resistance Level | $17.29 | $41.62 |
| Average True Range (ATR) | 0.44 | 3.29 |
| MACD | -0.33 | -2.12 |
| Stochastic Oscillator | 22.05 | 5.12 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.